Expert Interviews

Acoramidis Reduces Atrial Fibrillation Burden in ATTR-CM: ESC 2025 Insights
ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
Advertisement
Holger Eltzschig, MD, PhDPreventive Cardiology | May 27, 2025
BMAL1-HIF2α link explains why AM heart attacks hit harder—new findings may lead to time-based cardioprotective therapies.
Mark GoddardHeart Failure | May 23, 2025
AI-driven ECGs are transforming heart failure care—enabling early detection, cutting costs, and expanding access.
Payal Kohli, MD, FACCHypertension | May 19, 2025
Dr. Payal Kohli dives into new tech and AI reshaping how we diagnose and manage hypertension.
Payal Kohli, MD, FACCHypertension | May 16, 2025
Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter.
CardioNerdsCardioNerds | May 12, 2025
Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research.
CardioNerdsCardioNerds | May 2, 2025
Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM.
CardioNerdsCardioNerds | May 5, 2025
Dr. Daniel Judge talks to the CardioNerds about a pivotal study in ATTR-CM.
CardioNerdsAHA 2024: CardioNerds | February 5, 2025
Dr. Kevin Alexander speaks with The CardioNerds about the importance of providing swift treatment to patients with ATTR-CM.
CardioNerdsAHA 2024: CardioNerds | February 5, 2025
The CardioNerds, Dr. Alexander discuss how acoramidis therapy works, and details data Dr. Alexander presented at AHA 2024.
Kevin M. Alexander, MDAHA 2024: CardioNerds | January 30, 2025
Dr. Georgia Vasilakis Tsatiris of The CardioNerds speaks to Dr. Kevin Alexander about the impact of ATTR-CM.
Advertisement
Advertisement
Advertisement